Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

MS Patient Fights FDA Over Rejection Of Genzyme's Lemtrada

|Includes:Sanofi (SNY)

You may be interested in this recent press from the Boston Business Journal,

A 49-year-old mother from Waterford, Conn., has become an ally of Cambridge, Mass.-based drug giant Genzyme in its efforts to get U.S. regulators to change their minds about the first-ever once-a-year drug to treat multiple sclerosis.

Click to enlarge

Melissa Burdick is a 49-year-old patient with multiple sclerosis who filed a citizen's petition in hopes of overturning the FDA's rejection of Lemtrada.

According to its author, this is a

"cool story on a Connecticut woman who may do more than a multi-billion dollar drug company can to change the FDA's mind on a potential $3.5B drug for multiple sclerosis."

Stocks: SNY